

## Community Pharmacy Nottingham and Nottinghamshire ICB News

A newsletter for Community Pharmacy Teams in Nottingham,  
Nottinghamshire and Bassetlaw

### Purpose of this newsletter

The purpose of this newsletter is to share news from across the health system with Community Pharmacy Teams. Please share this newsletter with everyone in your pharmacy team including any locum staff.

### In this issue

|  |   |
|--|---|
| Pharmacy First Update.....   | 2 |
| CPAF Screening.....  | 3 |
| Podcasts from the Area Prescribing Committee (APC).....                            | 3 |
| Community Pharmacy PCN engagement lead Expressions of Interest .....               | 3 |
| GnRH Analogues for puberty suppression for gender dysphoria and incongruence ..... | 3 |
| Questions and feedback about this newsletter.....                                  | 4 |

## Pharmacy First Update

Nick Hunter from Community Pharmacy Nottingham and Rebecca Dickenson Community Pharmacy Clinical lead attended the Healthwatch event on Tuesday 23<sup>rd</sup> July to help promote Pharmacy First.



CPPE continue to provide materials to help with the provision of Pharmacy first and this list can be viewed on the CPPE website here; [CPPE News: CPPE resources for the NHS Pharmacy First service](#).

## CPAF Screening

The deadline for CPAF screening questionnaires is the Wednesday 31<sup>st</sup> July 2024.

## Podcasts from the Area Prescribing Committee (APC)

The eleventh episode of the APC podcast about Vitamin D is available on Spotify, and can also be found on the APC website in the [Podcast section](#).

## Community Pharmacy PCN engagement lead Expressions of Interest

Expressions of interest are being sought for Community Pharmacy PCN engagement leads to work across the four Nottingham and Nottinghamshire ICB places:

- Nottingham City
- South Notts
- Mid Notts
- Bassetlaw

The purpose of this function is to help increase engagement with Pharmacy First Services. More information and how to express interest will be sent by email to Community Pharmacy NHS net emails.

## GnRH Analogues for puberty suppression for gender dysphoria and incongruence

GnRH analogues are no longer permitted to be prescribed for puberty suppression in gender dysphoria.

Due to this change, when prescribing for other indications (e.g. cancer), the script will need to be marked "SLS" in order for the pharmacist to be able to dispense.

| 07/2024 Part XVIII B<br>DRUGS, MEDICINES AND OTHER SUBSTANCES THAT MAY BE ORDERED ONLY IN<br>CERTAIN CIRCUMSTANCES  |  |  |
|---|--|--|
| In England:<br>Part XVIII B reproduces Schedule 2 to the National Health Service (General Medical Services Contracts) (Prescription of Drugs etc.) Regulations 2004.<br>Drugs in Column 1 of this part may be prescribed for persons mentioned in Column 2, only for the treatment of the purpose specified in Column 3. The Prescriber must endorse the prescription with the reference "SLS".<br>Details of restricted availability appliances (vacuum pumps and constrictor rings for erectile dysfunction) can be found in Part IX of the Drug Tariff beside the listing for the relevant appliance.<br>* "at clinical risk" means in relation to a patient, a patient who -<br>(a) has chronic respiratory disease;<br>(b) has asthma that requires continuous or repeated use of inhaled or systemic steroids or with previous exacerbations requiring hospital admission;<br>(c) has chronic heart disease;<br>(d) has chronic renal failure;<br>(e) has chronic liver disease;<br>(f) has chronic neurological disease;<br>(g) has diabetes; or<br>(h) is immunosuppressed. |  |  |
| Drug  | Patient  | Purpose  |
| Clobazam  | Any patient  | Epilepsy   |
| GnRH analogue   | (1) Any patient who is aged 18 or over   | (1) Treatment for any purpose  |
| Note: "gonadotrophin-releasing hormone" ("GnRH") analogue means a medicinal product that consists of or contains buserelin, gonadorelin, goserelin, leuprorelin acetate, nafarelin or triptorelin   | (2) Any patient who is aged under 18 to whom the practitioner is providing treatment under the contract which does not include treatment for the purpose of puberty suppression in respect of gender dysphoria, gender incongruence or a combination of both | (2) Treatment for any purpose other than treatment for the purpose of puberty suppression in respect of gender dysphoria, gender incongruence or a combination |

[Questions and feedback about this newsletter](#)

If you have any questions, please email the ICB Community Pharmacy Clinical lead;  
Rebecca Dickenson using the email address [Rebecca.Dickenson7@nhs.net](mailto:Rebecca.Dickenson7@nhs.net).

Please send feedback as it helps to tailor this newsletter for you and your team.